Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott GMP Investments “Pay Off” In Pharma, Despite Diagnostics Setback

Executive Summary

Abbott's efforts to address quality control issues in the diagnostics division have had a beneficial effect on the company's GMP compliance status in pharmaceuticals, the company told a June 11 conference call

You may also be interested in...



Abbott Hospital Products Spin-Off Will Free Up $500 Mil. For Rx Spending

Abbott's planned spin-off of a new hospital products company will free up approximately $500 mil. to invest in R&D and promotional support for Humira

Abbott Hospital Products Spin-Off Will Free Up $500 Mil. For Rx Spending

Abbott's planned spin-off of a new hospital products company will free up approximately $500 mil. to invest in R&D and promotional support for Humira

Abbott Upgrading Texas Rx Plant Following GMP Warning Letter

Abbott is accelerating enhancement of the monitoring system validation program for manufacturing at its Austin, Tex. facility following receipt of an FDA warning letter

Related Content

UsernamePublicRestriction

Register

PS039996

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel